LMCC Review Lecture Pediatric Respiratory Medicine
description
Transcript of LMCC Review Lecture Pediatric Respiratory Medicine
![Page 1: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/1.jpg)
LMCC Review Lecture
Pediatric Respiratory Medicine
Joe Reisman MD, FRCP(C), MBAPediatric Respirologist
Chief of Pediatrics, CHEOProfessor and Chairman, Department of Pediatrics
Faculty of Medicine, University of Ottawa
![Page 2: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/2.jpg)
![Page 3: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/3.jpg)
Normal Respiratory Rates
Age Respiratory Rate (breaths/min)
Neonates 30-60Infant 20-501 yr 20-402 yr 20-353 yr 15-30Adolescent 12-18
![Page 4: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/4.jpg)
Asthma Definition
• Asthma is characterized by paroxysmal or persistent symptoms such as dyspnea, chest tightness, wheezing, sputum production and cough associated with variable airflow limitation and hyperresponsiveness to endogenous or exogenous stimuli
• Inflammation key to underlying mechanism for development and persistence of Asthma
![Page 5: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/5.jpg)
![Page 6: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/6.jpg)
![Page 7: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/7.jpg)
![Page 8: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/8.jpg)
“Not All that Wheezes is Asthma”Differential Diagnosis
• Infections
– Bronchiolitis– Respiratory viruses– Pertussis– Sinusitis
• Inflammatory
– Asthma– Tuberculosis– Bronchopulmonary
Dysplasia– Cystic Fibrosis
![Page 9: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/9.jpg)
“Not All that Wheezes is Asthma”Differential Diagnosis
• Aspiration– Gastroesophageal
reflux– Palatopharyngeal
dyscoordination– Foreign body
• Congenital Malformations– Vascular rings– Congenital cysts etc.
• Miscellaneous– Congestive heart
failure– Vocal chord adduction– Psychogenic causes
![Page 10: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/10.jpg)
Clinical Features suggestive of an alternative diagnosis to asthma
History
Symptoms presenting in neonatal period
Requirement of ventilation in newborn period
Wheeze associated with feeding or vomiting
Sudden onset of cough/choking
Steatorrhea
Stridor
![Page 11: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/11.jpg)
Clinical features suggestive of an alternative diagnosis to asthma
Physical Examination
Failure to thrive
Significant heart murmur
Clubbing
Unilateral signs
![Page 12: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/12.jpg)
Clinical features suggestive of an alternative diagnosis to asthma
Investigations
No reversibility of airflow obstruction with bronchodilator
Focal, persistent or atypical radiographic findings
![Page 13: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/13.jpg)
Making the Diagnosis
• History, Physical, Supporting Investigations• History of recurrent episodes of cough, wheeze,
shortness of breath, chest tightness• Evidence of Atopy (history, physical, eosinophilia, family
history)• Evaluate and exclude alternate diagnoses• Pulmonary function testing (6 years and older)
– FEV1 and response to bronchodilator
Response to Therapeutic Trial– Short-acting bronchodilators– Anti-inflammatory agents
![Page 14: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/14.jpg)
Types of Asthma in Young Children
• Early Onset, Transient– Non-Atopic– Outgrown in approximately 60% children
• Early Onset, Persistent– Associated with Atopy– Personal Atopy– Family History of Atopy
![Page 15: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/15.jpg)
Guideline Recommendations regarding Diagnosis
• 1. Physicians must obtain appropriate patient and family history to assist them in recognizing the heterogeneity of wheezing phenotypes in pre-school aged children (Level III)
• 2. In children unresponsive to asthma therapy, physicians must exclude other pathology that might suggest an alternative diagnosis (Level IV)
• 3. The presence of atopy should be determined because it is a predictor of persistent asthma (Level III)
![Page 16: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/16.jpg)
Determination of Asthma Severity and Control
• Severity may only be able to be determined once adequate asthma control is achieved
• Asthma control should be assessed on a regular basis (continuity of care)
• Base assessment of control on following criteria
![Page 17: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/17.jpg)
Parameter Frequency or Value
Daytime Symptoms < 4 days/week
Night-time Symptoms <1 night/week
Physical Activity Normal
Exacerbations Mild, infrequent
School Absence None
Beta-2 Agonist need <4 doses/week
FEV1 or PEF >90% personal best
PEF diurnal variation < 10-15%
Criteria for Determining whether Asthma is Controlled
![Page 18: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/18.jpg)
Therapeutic Goals
• Achieve and maintain acceptable asthma control• If poor control, identify reasons
– Environment– Education– Drug and Dose– Inhaler technique– Compliance issues
• Once good control is achieved, gradually reduce medication to minimum that maintains control, and reassess over time
![Page 19: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/19.jpg)
General Management of Asthma
• If control is inadequate, reason or reasons should be identified, maintenance therapy should be modified
• Any new treatment should be considered a therapeutic trial and its effectiveness should be assessed after 4-6 weeks
• Inhaled corticosteroids should be introduced as initial maintenance therapy (Level I) even when patient reports symptoms fewer than 3 times per week
• Although less effective than low dose ICSs, (Level I) LTRAs are alternative if patient can not or will not use ICSs (Level II)
• If control is inadequate on low-dose ICSs, assess reasons for poor control and consider additional therapy with long-acting B2-agonists or LTRAs (Level I).
• Severe asthma may require systemic corticosteroids• Asthma control and maintenance must be assessed regularly
![Page 20: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/20.jpg)
Frequent Reasons for Poor Asthma Control
• Insufficient patient education in terms of what asthma is, and how it is controlled
• Insufficient use of objective measures of airflow obstruction (PEF, FEV1), leading to over- or underestimation of asthma control
• Misunderstanding regarding role and side effects of medications
• Overuse of B2-agonists• Insufficient use of anti-inflammatory agents, including
intermittent use, inadequate use, or lack of use• Inadequate assessment of patient adherence• Lack of continuity of care
![Page 21: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/21.jpg)
Asthma Therapy
Environmental control Education, Written action plan, and Follow-up
Fast-acting bronchodilator on demand
Very mild Mild
Regularly assess:Regularly assess:ControlTriggersComplianceInhalerTechniqueCo-morbidity
Adjust maintenance therapy
Inhaled Corticosteroids
Add-on therapy
Pred
Moderate ModeratelySevere
Severe
![Page 22: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/22.jpg)
First Line Maintenance Therapy
• Physicians should recommend inhaled corticosteroids (ICSs) as the best option for anti-inflammatory therapy monotherapy for childhood asthma (Level I)
• There is insufficient evidence to recommend leukotriene receptor antagonists (LTRAs) as first-line monotherapy for childhood asthma (Level I). For children who can not or will not use ICSs, LTRAs represent an alternative (Level II)
![Page 23: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/23.jpg)
ICS Benefits (Budesonide)• Clinical measures of control strongly favored
Budesonide over Placebo– Symptoms– Rescue medication use and prednisone
courses– Episode-free days– Hospitalizations and urgent care– Initiation of beclomethasone or additional
asthma medicationCAMP Study, NEJM Oct 13, 2000
![Page 24: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/24.jpg)
Growth Effects of Budesonide
Budesonide growth effect
• Led to limited, small, and apparently transient reduction in growth velocity
• Projected final height by bone age similar to Placebo
![Page 25: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/25.jpg)
ICS Safety
Other safety issues for Budesonide
• No adverse effect on bone density
• No association with cataracts
• No adverse effect on sexual maturation
• No adverse effect on psychological growth
![Page 26: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/26.jpg)
Add-on Therapies
• Long-acting B2-agonists are not recommended as maintenance monotherapy for asthma (Level I)
• After reassessment of compliance, control of environment and diagnosis, if asthma is not optimally controlled with low doses of ICSs, therapy should be modified by the addition of a long-acting B2-agonist (Level I)
• Alternatively, addition of an LTRA or increasing to a moderate dose of ICS may be considered (Level1)
![Page 27: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/27.jpg)
Inhalation Devices
• At each contact, health care professionals should work with patients and their families on inhaler technique (Level I)
• When prescribing MDIs, physicians should recommend use of a valved spacer, with mouthpiece when possible, for all children (Level II)
• Dry powder breath-actuated devices offer a simpler form of maintenance therapy in children over 5 years of age (Level IV)
• Children tend to “auto-scale” their inhaled medication dose and the same dose of maintenance medication can be used at all ages for all medications (Level IV)
• Physicians, educators and families should be aware that jet nebulizers are rarely indicated for the treatment of chronic or acute asthma (Level I)
![Page 28: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/28.jpg)
Prevention Strategies for AsthmaPrimary Prevention
• With conflicting data on early life exposure to pets, no general recommendations can be made with regard to pets for primary prevention of allergy and asthma (Level III). Families with bi-parental atopy should avoid having cats or dogs in the home (Level II)
• There are conflicting and insufficient data for physicians to recommend for or against breastfeeding specifically for the prevention of asthma (Level III). Due to its many other benefits, breastfeeding should be recommended
![Page 29: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/29.jpg)
Prevention Strategies for AsthmaSecondary Prevention
• Health care professionals should continue to recommend the avoidance of tobacco smoke in the environment (Level IV)
• For patients sensitized to house dust mites, physicians should encourage appropriate environmental control (Level V)
• In infants and children who are atopic, but do not have asthma, data are insufficient for physicians to recommend other specific preventive strategies (Level II)
![Page 30: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/30.jpg)
Our Patients and their Parents Still Smoke…..
![Page 31: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/31.jpg)
50% of Children with Asthma are Sensitive to House Dust Mite
![Page 32: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/32.jpg)
Prevention Strategies for AsthmaTertiary Prevention
• Allergens to which a person is sensitized should be identified (Level I), and a systematic program to eliminate, or at least to substantially reduce, allergen exposure in sensitized people should be undertaken (Level II)
![Page 33: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/33.jpg)
EDUCATION
![Page 34: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/34.jpg)
Education and Follow-up
• Asthma control criteria should be assessed at each visit (Level IV). Measurement of pulmonary function, preferably by spirometry, should be done regularly (Level III) in adults and children over 6 years of age
• Socioeconomic and cultural factors should be taken into account in designing asthma education programs (Level II).
• School age children may benefit from education programs separate from their parents
![Page 35: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/35.jpg)
![Page 36: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/36.jpg)
![Page 37: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/37.jpg)
![Page 38: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/38.jpg)
![Page 39: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/39.jpg)
![Page 40: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/40.jpg)
![Page 41: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/41.jpg)
![Page 42: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/42.jpg)
OXYGEN
![Page 43: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/43.jpg)
Asthma Rx
![Page 44: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/44.jpg)
![Page 45: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/45.jpg)
![Page 46: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/46.jpg)
Differential Diagnosis of Croup
• Epiglottitis
• Bacterial Tracheitis
• Foreign Body in Airway or Esophagus
![Page 47: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/47.jpg)
Management of Croup
• Avoid agitation as much as possible• Mild croup may be managed at home with p.o.
fluids and humidity• Warn parents croup may be:• Worse at night• May clear in cold air outside
![Page 48: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/48.jpg)
Management of Croup cont’d
• Stridor at rest, moderate chest wall retractions, and an anxious, restless child are all indicators of moderate to severe disease and signal need for hospitalization
• Nurse in Oxygen (usually 30-40%)• If concerned about degree of respiratory failure,
arterial blood gas indicated
![Page 49: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/49.jpg)
Management of Croup cont’d
• Racemic epinephrine 0.5 mL of 2.25% solution in 3 mL normal saline by inhalation X 1 dose may provide relief
• Effect may last 30-60 minutes; may repeat q1-2h• Dexamethasone 0.6 mg/kg (MAX: 12 mg) (PO,
IM, IV) X 1 dose• A child who has received racemic epinephrine
should be admitted for observation
![Page 50: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/50.jpg)
Management of Croup cont’d
• If there is a question of impending respiratory failure, obtain arterial blood gases
• A rising respiratory rate correlates well with a falling PaO2
• Hypercapnea (rising PaCO2) occurs late in upper respiratory tract obstruction and is a sign of increasing respiratory failure
![Page 51: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/51.jpg)
Bronchiolitis
• Affects approximately 50% children < 2 years of age• Peak incidence 6-8 months, winter, spring• RSV accounts for >50% of cases• Parainfluenza type 3, influenza, adenovirus, ?rhinovirus
can also be causes• Usually viral prodrome with cough, URTI symptoms• Most often mild disease• Can affect those with underlying cardiac, lung disease
more severely
![Page 52: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/52.jpg)
Bronchiolitis cont’d
• Wheezing, tachypnea, tachycardia, respiratory distress lasting 5-7 days
• CXray may show hyperinflation, increased peribronchial markings, areas of atelectasis, linear densities
• NP swab to detect viral etiology (immunofluorescence)• Oximetry - keep O2 sat > 92% with humidified O2• Trial of salbutamol or racemic epinephrine• Admit if persistent tachypnea, respiratory distress, very young
infants, persistent hypoxia• Antibiotics have no role unless also suspect complicating bacterial
disease
• Consider prophylaxis of those high risk patients (BPD, cardiac disease etc.) with Palivizumab (monoclonal antibody against RSV) monthly during RSV season
![Page 53: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/53.jpg)
![Page 54: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/54.jpg)
Management of Pneumonia- Investigations
• CBC, differential count• Blood culture• Sputum for culture (if child is old enough)• Arterial blood gas if respiratory distress• Tuberculin skin test with Candida control• Cold agglutinin titer• Chest X-ray PA and Lat• Diagnostic thoracentesis if significant amount of
pleural fluid
![Page 55: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/55.jpg)
Management of Pneumonia- Treatment
• General supportive care including PO or IV fluids
• O2 as needed
• IV or PO antibiotics appropriate for most likely etiologic organism or organism cultured
• Admission based on clinical status• Empyema requires chest tube drainage• Consider anaerobic coverage if aspiration a
possibility
![Page 56: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/56.jpg)
Pneumonia- Treatment
![Page 57: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/57.jpg)
Pertussis
• Pertussis is an important cause of chronic cough• The Chinese named Pertussis “the 100 Day
Cough”• Immunization does not guarantee protection
from Pertussis• Cough may have classic “inspiratory whoop” in
chronic phase
![Page 58: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/58.jpg)
Chlamydia Pneumonia
![Page 59: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/59.jpg)
Chlamydia Pneumonia
![Page 60: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/60.jpg)
TB remains an important infection!
![Page 61: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/61.jpg)
Measure the induration when performing a 5-TU tuberculin skin test
![Page 62: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/62.jpg)
RDS- Early Changes
![Page 63: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/63.jpg)
BPD- late changes
![Page 64: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/64.jpg)
Case Presentation- Patient L.M.
• 40 day old infant admitted to CHEO January 15 2003, with 4 day Hx of wheezy illness; RSV +ve
• Hx intermittent cough since 2 weeks of age• Slow weight gain since birth; B.W. 3640g; weight on
admission 4080g• Hx of “greasy” stools• Meconium took about 2 weeks to pass• Hx of hypo echoic bowel on prenatal ultrasound• O/E scrawny infant with crackles over left anterior and
lateral chest; wheezes bilaterally• Sweat Chloride Tests x 2: 82 and 91 mEq/L
![Page 65: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/65.jpg)
![Page 66: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/66.jpg)
![Page 67: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/67.jpg)
![Page 68: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/68.jpg)
![Page 69: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/69.jpg)
![Page 70: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/70.jpg)
![Page 71: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/71.jpg)
![Page 72: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/72.jpg)
![Page 73: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/73.jpg)
![Page 74: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/74.jpg)
![Page 75: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/75.jpg)
![Page 76: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/76.jpg)
![Page 77: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/77.jpg)
![Page 78: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/78.jpg)
![Page 79: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/79.jpg)
![Page 80: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/80.jpg)
![Page 81: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/81.jpg)
![Page 82: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/82.jpg)
![Page 83: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/83.jpg)
![Page 84: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/84.jpg)
![Page 85: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/85.jpg)
![Page 86: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/86.jpg)
![Page 87: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/87.jpg)
![Page 88: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/88.jpg)
![Page 89: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/89.jpg)
Psychosocial Issues
• Both Parents and Patients can present with a wide array of psychosocial issues
• Coping with a chronic condition
• Compliance Issues
• Adolescence Issues
• Death and Dying Issues
• Issues regarding drug plans and financial support
![Page 90: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/90.jpg)
![Page 91: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/91.jpg)
![Page 92: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/92.jpg)
![Page 93: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/93.jpg)
![Page 94: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/94.jpg)
Agents Aimed at Altering Properties of CF Mucus
• N-acetylcysteine- no longer used due to bronchial irritability
• Recombinant Human DNase (dornase alpha)- breaks down DNA from dead neutrophils; administered as 2.5 mg once daily by aerosol. Studies of sustained improvement or decreased decline in PFT’s have yielded mixed results (Ramsey et al, Am Rev Respir Dis, 1993); (Fuchs et al, NEJM 1994)
• Not an inexpensive therapy
![Page 95: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/95.jpg)
![Page 96: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/96.jpg)
![Page 97: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/97.jpg)
![Page 98: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/98.jpg)
![Page 99: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/99.jpg)
![Page 100: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/100.jpg)
![Page 101: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/101.jpg)
![Page 102: LMCC Review Lecture Pediatric Respiratory Medicine](https://reader035.fdocuments.us/reader035/viewer/2022062409/56814c57550346895db9745c/html5/thumbnails/102.jpg)